Abstract #0708

Hyperpolarized 13C MRI of Patients with Metastatic Prostate Cancer to Bone and Liver

Hsin-Yu Chen¹, Philip Lee¹, Zi Zhu¹, Robert A. Bok¹, Michael A. Ohliger¹, Jeremy W. Gordon¹, Mark van Criekinge¹, Lucas Carvajal¹, James B. Slater¹, Peder E.Z. Larson¹, Pamela N. Munster², Rahul Aggarwal², John Kurhanewicz¹, and Daniel B. Vigneron¹

¹Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²School of Medicine, University of California, San Francisco, San Francisco, CA, United States

In this feasibility study, hyperpolarized ¹³C-pyruvate MR exams were conducted on 5 patients who had metastatic prostate cancer to bone or liver. In one man with liver metastasis, serial scans showed a decrease of pyruvate-to-lactate conversion k_PL (0.026 to 0.015 s^-1) at 2 months after initiation of chemotherapy that was consistent with response based on PSA and RECIST criteria. High k_PL was found in patients with bone lesions comparable to that in high-grade primary prostate cancer. Overall, HP-¹³C MR imaging showed great promise as a biomarker to evaluating treatment responses in metastatic prostate cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here